stockportfolio.pro
Stocks / BMY vs ELV
BMY vs ELV
Bristol-Myers Squibb Company and Elevance Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bristol-Myers Squibb Company (BMY) | Elevance Health, Inc. (ELV) | |
|---|---|---|
| Market cap | $114.8B | $87.3B |
| Revenue (latest FY) | $48.19B | $197.58B |
| Net income (latest FY) | $7.05B | $5.66B |
| Revenue growth (5y CAGR) | 2.5% | 10.1% |
| Net margin | 14.6% | 2.9% |
| Return on equity | 38.2% | 12.9% |
| P/E ratio | 15.8 | 17.0 |
| Dividend yield | 4.4% | 1.7% |
| Profitable years (of last 10) | 8 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BMY — free Open ELV — freeFrequently asked questions
Which is bigger, BMY or ELV?
Bristol-Myers Squibb Company is larger by market capitalization — $114.8B versus $87.3B.
Which grows faster, BMY or ELV?
Over the last five fiscal years, Elevance Health, Inc. grew revenue faster — 10.1%/yr versus 2.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.